Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program.

摘要

Na?ve and experienced patients with advanced fibrosis or cirrhosis due to HCV-1 who have compensated bone marrow and liver function, can effectively and safely be treated by TVR triple therapy. Baseline predictors of outcome have been identified to optimize pre-treatment counselling.